Loading...
GMAB logo

Genmab A/SNasdaqGS:GMAB Stok Raporu

Piyasa Değeri US$20.6b
Hisse Fiyatı
n/a
1Y23.2%
7D7.2%
1D0.4%
Portföy Değeri
​
Görünüm

Genmab A/S

NasdaqGS:GMAB Stok Raporu

Piyasa değeri: US$20.6b

Genmab (GMAB) Hisse Özeti

Bir biyoteknoloji şirketi olan Genmab A/S, Danimarka'da kanser ve diğer hastalıkların tedavisi için antikor bazlı ürünler ve ürün adayları geliştirmektedir. Daha fazla detay

Ödüller

Adil değer tahminimizden 52.8% daha düşük bir oranda işlem görüyor

Kazançların yılda 19.39% oranında artması öngörülüyor

Risk Analizi

Borç işletme nakit akışı tarafından iyi karşılanmıyor

Kar marjları (19.1%) geçen yılın (37.6%) altında

Finansal sonuçları etkileyen büyük tek seferlik kalemler


GMAB Community Fair Values

Create Narrative

See what 45 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW425,651 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
425,651 investors already sharing narratives
View all narratives

Genmab A/S Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Genmab
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıDKK 34.54
52 Haftanın En Yüksek SeviyesiDKK 35.43
52 Haftanın En Düşük SeviyesiDKK 23.62
Beta0.70
1 Aylık Değişim4.78%
3 Aylık Değişim36.66%
1 Yıllık Değişim23.16%
3 Yıllık Değişim-5.36%
5 Yıllık Değişim-23.05%
Halka arzdan bu yana değişim863.86%

Son Haberler & Güncellemeler

Seeking Alpha • Jul 22

Genmab: Multiple Late-Stage Readouts Ahead

Summary Genmab has underperformed so far this year despite strong commercial performance and largely positive pipeline news flow. Strong Q2 royalty product sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y) support expectations for a revenue beat and upward guidance revision. The company expects to report topline results from up to five late-stage trials of Epkinly, petosemtamab, and Rina-S. I remain optimistic on all five upcoming readouts and expect them to market the start of a new growth phase for Genmab but acknowledge competitive and clinical trial risks. In today's article, I provide a preview of these readouts. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jul 22

Genmab: Multiple Late-Stage Readouts Ahead

Summary Genmab has underperformed so far this year despite strong commercial performance and largely positive pipeline news flow. Strong Q2 royalty product sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y) support expectations for a revenue beat and upward guidance revision. The company expects to report topline results from up to five late-stage trials of Epkinly, petosemtamab, and Rina-S. I remain optimistic on all five upcoming readouts and expect them to market the start of a new growth phase for Genmab but acknowledge competitive and clinical trial risks. In today's article, I provide a preview of these readouts. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Genmab's Outlook Beyond Darzalex's Patent Cliff

Summary Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company’s robust late-stage pipeline could offset DARZALEX revenue loss with new product launches expected between 2027-2031. Genmab’s strong balance sheet with $2.9 billion in cash and no long-term debt provides financial flexibility for R&D and strategic acquisitions. The current valuation aligns with a conservative scenario where all new product launches fail suggesting limited downside risk but strong upside potential. If Phase 3 trials succeed, Genmab could see massive growth in revenue and potentially double or triple its market value, making it a low-risk, high-reward investment. Read the full article on Seeking Alpha
Seeking Alpha • Mar 14

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Summary Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Concerns about GEN3014's safety may have impacted investors' perceptions of Genmab’s HexaBody platform. Genmab has only one early-stage HexaBody candidate in the clinic. Focus should now shift to quarterly results and upcoming clinical data updates, starting with proof-of-concept results for Rina-S in endometrial cancer and updated phase 2 results for acasunlimab. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Genmab Is Too Attractive To Ignore

Summary Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio. Continued strong topline growth, increasing cash flows, renewed margin expansion and pipeline maturation should drive a share price recovery in 2025 and beyond. Read the full article on Seeking Alpha
Seeking Alpha • Nov 06

Genmab: Looking To Manage My Position Around Q3 Earnings

Summary Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab’s pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition. Despite risks, including competition and regulatory challenges, I maintain a strong conviction in GMAB, planning to add shares if positive earnings trigger a price move above $24. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Summary Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year. Operating margin pressure continues, acquisition of ProfoundBio extends the time to recovery by several quarters. Continued commercial and pipeline progress and the eventual return of margin expansion position Genmab well for long-term value creation. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Genmab: A Complicated Tale

Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contribute significantly to its revenue. Genmab has a strong pipeline with eight revenue-generating medications, nine clinical programs, and nine royalty candidates in Phase 2 or later trials. The company also recently made an acquisition to bolster its pipeline with some ADC candidates. A full investment analysis around Genmab A/S stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Genmab Acquires A Missing Piece For Its Pipeline

Summary Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to advance ProfoundBio's lead candidate, Rina-S, to registrational trials with a potential approval as early as 2027. Rina-S has generated promising efficacy and safety in an early stage clinical trial in patients with ovarian and endometrial cancer. The ADC market is increasingly crowded, but an important market Genmab needs to expand into. Read the full article on Seeking Alpha
Seeking Alpha • Feb 21

Genmab: Recent Updates Support The Growth Narrative

Summary Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024. The company's pipeline includes promising candidates and collaborations with industry giants, supporting future growth. Risks to consider include legal disputes and competition, but overall, Genmab's growth narrative remains intact. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Summary Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company. Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth and pipeline progression and expansion. The launch of Epkinly/Tepkinly and the growth of other products are expected to reduce Genmab's reliance on Darzalex royalties. The head-to-head phase 2 data of GEN3014 and Darzalex represent the most important clinical catalyst for Genmab this year. Read the full article on Seeking Alpha
Seeking Alpha • Jan 12

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Summary Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regulatory approvals in multiple regions. DARZALEX, Genmab's flagship product, continues to be a substantial revenue driver, and investors should monitor its clinical programs for potential growth. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab (GMAB) has announced Q3 worldwide net trade sales of $2.05B for Darzalex (daratumumab) anti-cancer monoclonal antibody medication, compared with $1.99B generated in Q2. Net trade sales were USD 1.09B in the U.S. and USD 955M in the rest of the world. Genmab (GMAB) receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to Johnson & Johnson (JNJ) subsidiary Janssen Biotech to develop, manufacture and commercialize daratumumab.
Seeking Alpha • Aug 08

Genmab improves FY 2022 guidance

Genmab (GMAB) improves FY 2022 guidance expects its 2022 revenue to be in the range of DKK 12,000M – 13,000M, an increase to the previous guidance of DKK 11,000M – 12,000M, driven primarily by the continued strong growth of DARZALEX net sales as well as the positive impact of the strong U.S. Dollar.  Such royalties are based on Genmab’s revised estimate of DARZALEX 2022 net sales of USD 7.8B – 8.2B compared to Genmab’s previous estimate of USD 7.5B – 8.0B. Anticipates its 2022 operating expenses to be in the range of DKK 7,600M – 8,200M, an increase to the previous guidance of DKK 7,200M – 7,800M, driven by increased investment related to pipeline progression and epcoritamab launch readiness activities as well as the negative impact of the strong U.S. Dollar. Operating profit to be in the range of DKK 3,800M – 5,400M, an increase to the previous guidance of DKK 3,200M – 4,800M.
Seeking Alpha • Jul 19

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab (GMAB) said global net sales of Darzalex reported by Johnson & Johnson (JNJ) rose 38.6% to $1.99B in Q2. Net trade sales were USD 1.02B in the U.S. and $965M in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous formulations, under an license agreement with J&J unit Janssen Biotech. Shares are up 2.84% premarket.
Seeking Alpha • Jun 28

Genmab: A Royalty Powerhouse With A Strong Pipeline

Genmab is receiving substantial and growing royalties from big pharma partners. The royalties are helping the company build its pipeline and to establish its own commercial infrastructure. Epcoritamab could be Genmab's next blockbuster. The stock is not cheap but increasing investments should lead to increased profits in the long run.

Hissedar Getirileri

GMABUS BiotechsUS Pazar
7D7.2%1.2%0.5%
1Y23.2%37.1%12.0%

Getiri vs. Endüstri: GMAB geçen yıl % 37.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: GMAB geçen yıl % 12 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement4.2%
Biotechs Industry Average Movement9.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

İstikrarlı Hisse Senedi Fiyatı: GMAB son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: GMAB 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
19983,119Jan G.J. de Winkelwww.genmab.com

Bir biyoteknoloji şirketi olan Genmab A/S, Danimarka'da kanser ve diğer hastalıkların tedavisi için antikor bazlı ürünler ve ürün adayları geliştirmektedir. Şirket, relaps veya refrakter (R/R) diffüz büyük b-hücreli lenfoma (DLBCL), büyük B-hücreli lenfoma ve foliküler lenfomalı (FL) yetişkin hastalar için EPKINLY ve TEPKINLY; ve kemoterapi sırasında veya sonrasında hastalık progresyonu olan rekürren/metastatik serviks kanserli yetişkin hastalar için Tivdak'ı pazarlamaktadır. Ayrıca R/R DLBCL ve FL, birinci basamak DLBCL ve FL, B hücreli non-Hodgkin lenfoma, R/R kronik lenfositik lösemi ve Richter sendromu ve pediatrik hastalarda agresif olgun B hücreli neoplazmlar için Epcoritamab; solid tümörler için tisotumab vedotin geliştirmektedir; solid tümörler ve küçük hücreli dışı akciğer kanseri (NSCLC) için Acasunlimab; platine dirençli yumurtalık kanseri ve solid tümörler için Rinatabart Sesutecan; solid tümörler için GEN1059, GEN1055 ve GEN1057; ve ileri solid tümörler için GEN1286.

Genmab A/S Temel Bilgiler Özeti

Genmab'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
GMAB temel i̇stati̇sti̇kler
Piyasa değeriUS$20.59b
Kazançlar(TTM)US$788.00m
Gelir(TTM)US$4.13b
26.1x
F/K Oranı
5.0x
P/S Oranı

GMAB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
GMAB gelir tablosu (TTM)
GelirUS$4.13b
Gelir MaliyetiUS$288.00m
Brüt KârUS$3.84b
Diğer GiderlerUS$3.06b
KazançlarUS$788.00m

Son Raporlanan Kazançlar

Jun 30, 2026

Sonraki Kazanç Tarihi

Nov 05, 2026

Hisse başına kazanç (EPS)13.19
Brüt Marj93.03%
Net Kâr Marjı19.08%
Borç/Özkaynak Oranı86.2%

GMAB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/09/17 06:29
Gün Sonu Hisse Fiyatı2026/09/17 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Genmab A/S 38 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays